Study on the Anti-Ulcerative Colitis Effect of Pseudo-Ginsenoside RT4 Based on Gut Microbiota, Pharmacokinetics, and Tissue Distribution.

RT4 intestinal flora pharmacokinetics tissue distribution ulcerative colitis

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
09 Jan 2024
Historique:
received: 09 12 2023
revised: 04 01 2024
accepted: 07 01 2024
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: epublish

Résumé

The purpose of this study was to explore the therapeutic effect of the oral administration of pseudo-ginsenoside RT4 (RT4) on ulcerative colitis (UC), and to determine the rate of absorption and distribution of RT4 in mice with UC. Balb/c mice were induced using dextran sulfate sodium salts (DSS) to establish the UC model, and 10, 20, or 40 mg/kg of RT4 was subsequently administered via gavage. The clinical symptoms, inflammatory response, intestinal barrier, content of total short-chain fatty acids (SCFAs), and gut microbiota were investigated. Caco-2 cells were induced to establish the epithelial barrier damage model using LPS, and an intervention was performed using 4, 8, and 16 µg/mL of RT4. The inflammatory factors, transient electrical resistance (TEER), and tight-junction protein expression were determined. Finally, pharmacokinetic and tissue distribution studies following the intragastric administration of RT4 in UC mice were performed. According to the results in mice, RT4 decreased the disease activity index (DAI) score, restored the colon length, reduced the levels of pro-inflammatory cytokines (TNF-

Identifiants

pubmed: 38255909
pii: ijms25020835
doi: 10.3390/ijms25020835
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Innovation platform (base) and talent special project
ID : 20210502005ZP
Organisme : Key Research and Development Program of Jilin Province
ID : 20230204038YY

Auteurs

Hui Yu (H)

School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.

Caixia Wang (C)

School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.

Junzhe Wu (J)

School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.

Qianyun Wang (Q)

School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.

Hanlin Liu (H)

School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.

Zhuoqiao Li (Z)

School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.

Shanmei He (S)

School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.

Cuizhu Wang (C)

School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Research Center of Natural Drug, Jilin University, Changchun 130021, China.

Jinping Liu (J)

School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Research Center of Natural Drug, Jilin University, Changchun 130021, China.

Classifications MeSH